Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Clinical trial NCT05675683 · COMPLETED
Trial details
- NCT number
- NCT05675683
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-10-01
- Primary completion
- 2021-12-31
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.